



ASX & MEDIA RELEASE

4 JULY 2018

MEDLAB TRIAL OF CANNABIS FOR CANCER PAIN ON SCHEDULE, INITIAL DOCTOR FEEDBACK POSITIVE

- Patient recruitment underway for NanaBis™ advanced cancer pain trial
- Doctor feedback positive from initial prescribing of NanaBis™ under SAS scheme
- Recent publications around cannabis and opioids highlights the need for clinical trials

Australian medical life sciences company, Medlab Clinical Ltd (ASX: MDC), reports that its clinical trial of its cannabis-based medicine, NanaBis™, is on schedule with recruitment.

This coincides with separate positive feedback received from doctors who have been prescribing the medicine.

Under Therapeutic Goods Administration's Special Access Scheme (SAS), Medlab has approval to supply NanaBis™ to medical practitioners for use with patients suffering cancer pain.

Feedback from some doctors is that it is proving effective in decreasing reliance on opioids and in its speed of action, aided by delivery through Medlab's nano-particle spray, NanoCelle™.

These developments coincide with yesterday's publication in *The Lancet*¹ of research into the effectiveness of cannabis use in people with chronic non-cancer pain and who have been prescribed opioids.

This research is distinct from Medlab's work which is focused on standardising and validating CBD and THC blends derived from cannabis, being delivered by NanoCelle™ to speed absorption into the bloodstream.

According to Medlab's Managing Director, Dr Sean Hall, the value of feedback from prescribing doctors was that it validated the chemistry of NanaBis™ which is distinct from hemp or medicinal cannabis.

"We still have a way to go with collecting more feedback and progressing with our clinical trial but our commitment to the integrity of this medical process makes Medlab distinctive in this area," Dr Hall said.

Medlab has developed two cannabis-based medicines which have differing cannabis formulations – NanaBis™ for those with chronic cancer pain and NanaBidual™ for those suffering effects from chemotherapy.

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: DR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.

¹ Campbell, Gabrielle et al, "Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: Findings from a 4-year prospective cohort study, *The Lancet – Public Health*, Vol 3, July 2018
<https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667%2818%2930110-5/fulltext>